Pyxis Oncology

Contributing Author

Recent Articles by Pyxis Oncology

Oct-02	Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering PYXS GlobeNewswire
Sep-30	Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering PYXS -19.66% GlobeNewswire
Sep-29	Pyxis Oncology Announces Proposed Public Offering PYXS GlobeNewswire
Sep-09	Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PYXS -13.11% GlobeNewswire
Sep-08	Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) PYXS GlobeNewswire
Sep-08	Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board PYXS GlobeNewswire
Sep-01	Pyxis Oncology to Participate in Upcoming Investor Conferences PYXS +6.17% GlobeNewswire
Aug-13	Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PYXS -5.35% GlobeNewswire
Jun-30	Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones PYXS +5.24% GlobeNewswire
May-14	Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones PYXS -15.65% GlobeNewswire
May-13	Pyxis Oncology to Participate in Upcoming Investor Conferences PYXS GlobeNewswire
May-07	Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer PYXS PYXS +21.24% GlobeNewswire
Apr-17	Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 PYXS GlobeNewswire
Mar-23	Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results PYXS GlobeNewswire
Feb-03	Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity PYXS GlobeNewswire
Dec-18	Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PYXS -48.66% GlobeNewswire
Nov-03	Pyxis Oncology to Participate in Upcoming Investor Conferences PYXS +7.02% GlobeNewswire
Nov-03	Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results PYXS +7.02% GlobeNewswire
Oct-13	Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings PYXS -6.76% PYXS -6.38% GlobeNewswire
Oct-09	Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets PYXS +31.62% GlobeNewswire
Sep-30	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PYXS GlobeNewswire
Aug-21	Pyxis Oncology to Participate in September Investor and Industry Conferences PYXS +13.79% GlobeNewswire
Aug-14	Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update PYXS +5.61% PYXS +8.85% GlobeNewswire
Jun-30	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PYXS GlobeNewswire
May-15	Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update PYXS GlobeNewswire
May-14	Pyxis Oncology to Participate in Two Upcoming Investor Conferences PYXS -10.08% GlobeNewswire

Pyxis Oncology

Recent Articles by Pyxis Oncology

Upgrade your Finviz experience